Navigation Links
Isis Initiates Phase 2 Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
Date:10/29/2012

activity with no bleeding events observed. 

"ISIS-FXIRx is one of many maturing drugs in our pipeline and represents the broad applicability of our technology to develop novel drugs for many different diseases.  We believe that the safety profile observed thus far coupled with the robust activity we have seen for ISIS-FXIRx in both our Phase 1 study and preclinically, suggest that this drug could have a significant benefit for patients at risk of a thrombotic event.  Given the mechanism of Factor XI inhibition, we believe that the drug could be used broadly to prevent deep vein thrombosis or pulmonary embolism in many different therapeutic settings, including stroke, myocardial infarction and with surgeries such as knee or hip replacement, where additional safe and effective anti-thrombotic drugs are needed.  Our earlier work suggests that ISIS-FXIRx could be used in combination with existing therapies," said Sanjay Bhanot, M.D., Ph.D., vice president, clinical development and translational medicine at Isis. 

"TKA is one of the leading surgeries performed worldwide each year and is associated with a high incidence of venous thromboembolism," said Brett Monia, Ph.D., senior vice president, antisense drug discovery at Isis.  "By evaluating our drug in these patients, we will be able to directly compare the activity and safety of ISIS-FXIRx to a commonly prescribed anti-coagulant, enoxaparin.  With this proof-of-value data in hand, we believe that we will have a robust and comprehensive data package representing a significant licensing opportunity for us."

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic,
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
6. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
7. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
8. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
9. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
10. Empire Asset Management Co. Initiates Coverage on Transcept Pharmaceuticals Inc., (NASDAQ: TSPT)
11. Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015 For the Last Decade ... Life Throughout Europe, the Middle East ... Astellas Pharma EMEA is celebrating its 10 year anniversary. ... historic merger of Japanese pharmaceutical companies Yamanouchi and Fujisawa, ... turning science into value for patients through its unwavering ...
(Date:5/25/2015)... 26, 2015  China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based on the number of ... for the first quarter ended March 31, 2015. ... 13.6% compared to the first quarter of 2014 ... compared to RMB678.3 million in the first quarter of ...
(Date:5/22/2015)... CHAPEL HILL, N.C. , May 22, 2015 ... will be hosting its sixth Medical Affairs ... – 12:30PM (EDT) via a virtual roundtable to ... Outcomes Research." Best Practices, Medical Affairs ... for sharing insights about the key challenges they ...
Breaking Medicine Technology:Astellas Pharma EMEA Celebrates Its 10th Anniversary 2Astellas Pharma EMEA Celebrates Its 10th Anniversary 3Astellas Pharma EMEA Celebrates Its 10th Anniversary 4China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 11Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2
... 20 Cardiac Science Corporation (Nasdaq: ... ( AED ) and diagnostic cardiac monitoring devices, ... vital signs and spot check monitors ... Canada. OMRON Healthcare is a subsidiary of OMRON Corporation, the ...
... SHENYANG, China, Oct. 20 /PRNewswire-Asia-FirstCall/ -- ... leading China-based biotechnology,company focused on researching, developing, manufacturing and ... general,meeting of shareholders held on October 12, 2009. , ... shareholders re-elected Dr. Jing Lou and Mr.,Moujia Qi to ...
Cached Medicine Technology:Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 2Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 3Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 4Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 6
(Date:5/26/2015)... (PRWEB) May 26, 2015 Learning ZoneXpress ... line, Nutrition Education Cards . These cards have ... engaging photography and simple, easy-to-read text, these new educational ... . They offer practical nutrition tips and suggestions to ... titles available are: , + MyPlate: Eat for a ...
(Date:5/26/2015)... 2015 Writers and editors can ... Vasont® CCMS to make creating, editing, and managing ... component content management system (CCMS) software provider, certified ... oXygen XML Editor Version 17.0, Syncro Soft’s latest ... extension merges key editorial functionality of the Vasont ...
(Date:5/26/2015)... Ore. (PRWEB) May 26, 2015 ... association which provides talent development to credit union CEOs, ... for their employees to boost the bottom line. CUES ... program that has helped dozens of credit unions across ... According to a 2014-2015 Staff Benefits Report ...
(Date:5/26/2015)... DENVER (May 26, 2015) – As ... is also experiencing many of the growing pains felt ... one major issue that cannabis companies now have to ... paper and plastic that marijuana growers, dispensaries and consumers ... we see the opportunity to enhance our environment for ...
(Date:5/26/2015)... General Networks Corporation today announced ... alliance ensures joint customers will benefit from the ... expertise in building enterprise content and process management ... customers integrate, manage and operationalize their data and ... “Our customers are seeking tools to make better ...
Breaking Medicine News(10 mins):Health News:Learning ZoneXpress Introduces New Educational Resource for WIC, SNAP-Ed, and EFNEP 2Health News:Vasont Systems Certifies the Integration between the Vasont® Component Content Management System and oXygen® XML Editor 17.0 2Health News:CUES Expects a Positive Return on Wellness with hubbub health™ 2Health News:CUES Expects a Positive Return on Wellness with hubbub health™ 3Health News:Colorado Cannabis Business Expands its Recycling Initiative, to Encourage Marijuana Retailers to Keep Their Businesses Green 2Health News:Colorado Cannabis Business Expands its Recycling Initiative, to Encourage Marijuana Retailers to Keep Their Businesses Green 3Health News:General Networks Corporation Announces Alliance with MarkLogic 2
... patients who undergo chemotherapy or radiation expect a high number ... chemotherapy or radiation can diminish the quality of life for ... as nausea, he or she is more likely to develop ... and the type of cancer influence how many side effects ...
... Patients with rheumatoid arthritis who receive a more intensive ... remission of their disease, finds a new study.// ... patients with similar levels of disease to one of ... drugs to fight rheumatoid arthritis, along with steroid injections. ...
... people in every 100,000. It is most common in people ... Simple exercises performed at home may help patients with vertigo ... ,Researchers studied 70 patients who had a form of vertigo ... Participants reported experiencing episodes of nausea or a feeling of ...
... the Centers for Disease Control and Prevention says 30 percent ... percentile,// and 15 percent of children have a BMI above ... years and the National Institutes of Health report that overweight ... keeps them at high risk for heart disease, diabetes, high ...
... can be done to activate the cells to destroy tumors. ... // cancer may be due to different cell priming or ... found a method to activate the anti-cancer cells in mice. ... patients and separated the anti-cancer cells. The cells were stimulated ...
... A new study shows soy protein with isoflavones does ... mineral density, or cholesterol in postmenopausal women.// ... menopause is related to a decrease in bone mineral ... cholesterol. Some women have taken hormone therapy to offset ...
Cached Medicine News:
Panoramic styling that contours closely to the face and brow. Saddle bridge fits average to fuller noses. Adjustable temple hinge adjusts up or down, longer or shorter. Soft cushion behind ear for co...
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
Qualcraft Radiation Readers, Carbon Glasses. Protect yourself and have close-vision clarity....
The Bronze Metalite Constructed of optical-grade steel with bronze electroplate. Fitted lead side shields that create a seal to the front of the lenses for increased scatter protection....
Medicine Products: